Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * Is it feasible to obtain genetic test results within a timeframe that can help inform treatment decisions for individuals with PDAC? * Can the genetic test results provide information about how a tumour will respond to or resist treatment? Participants will: * Receive standard chemotherapy to treat their cancer. * Provide samples of their blood, tissue, and fluid for genetic testing. * Visit the clinic every 4 weeks for check-ups and tests. * Complete questionnaires every 12 weeks.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony rak trzustki, który można operować lub jest trudny do operacji
- •Wystarczająco dobre ogólne stany zdrowia do poddania się operacji
- •Uczestnictwo w programie genetycznym BC Cancer (POG)
- •Planowana chemioterapia lekami FOLFIRINOX lub gemcytabina
- •Wystarczająca liczba białych krwinek, hemoglobiny i płytek krwi
- •Wystarczające funkcjonowanie wątroby i nerek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
BC Cancer
Vancouver, Canada
Trial contact
Daniel J Renouf, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.